D oes high blood cholesterol affect coronary heart disease? Has the American public been urged inappropriately to take action on ' lowe ring blood cholesterol in an effort to prevent heart disease? Recently, the media and some scientific sources in the United States have raised questions about whether high blood cholesterol contributes to coronary heart disease (CHD), and whether lowering high blood cholesterol helps prevent heart disease.
The evidence is compelling. Data from epidemiologic, pathologic, metabolic, clinical , genetic, and animal studies demon strate that high blood cholesterol is a risk factor for heart disease, even in the absence of other risk factors, and that lowerin g blood cholesterol levels reduces the risk of CI-ID.
Several major clinical trials illustrate this substantial scientific base. They include the Coronary Primary Prevention Trial (CPPT), the Helsinki Heart Study, the Cholesterol Lowering Atherosclerosis Study (CLAS), and the Familial Atherosclerosis Trial Study.
The CPPT findings , released in 1984, demonstrated that each 1% reduction in total blood cholesterol results in a nearly 2% reduction in CHD risk. The Helsinki Heart study, released in 1987, employed drug treatment that not only reduced total and LDL cholesterol levels, but also raised HDL cholesterol levels (the so-called "good" cholesterol) and resulted in a 34% reduction in coronary events. The CLAS study showed through coronary angiography that cholesterol lowering with diet and drugs not onl y slows the progression of fatty plaques but, in some instances, reverse s plaque formation. Recent evidence from the Familial Atherosclerosis Treatment Study supports the previous studies and shows that atherosclerosis progression slows and regre ssion occurs with vigorou s cholesterol lowering.
In addition to the evidence demonstrating reductions in CHD mortalit y from lowering blood cholesterol, several trials demonstrated a reduction in total mortality. The Coronary Drug Project (COP) showed, in addition to the 29% reduction in heart attacks, a significant difference in overall mortality 9 years after drug treatment had been terminated . As with the COP, long term follow up of the Oslo Study of Diet and Antismoking Trial revealed a significant difference in CI-ID deaths between the intervention and control groups, and 5 years after completion of the trial, a 33% difference was noted in all-cause mortality between the two groups.
The Stockholm Ischemic Heart Disease Study of high risk individuals used a combination of diet and drug intervention. At the end of 5 years, the treated group had realized a substantial lowering of total cholesterol with the attendant reduction in CHD and total mortality. Elevated cholesterol levels are not just a risk factor for middle age men. CHD is the leading cause of death among women, and the CHD mortality rates rise markedly after menopause. Elevated blood cholesterol is an important contributor to this rise.
Furthermore, the Framingham Heart Study has shown that LDL cholesterol (the so-called "bad" cholesterol) is a predictor of CHD in the elderly and the Honolulu Heart Study has shown total cholesterol levels to be a predictor for CHD in the elderly. Because CHD is common in the elderly and in women after menopause , even modest reductions in risk offer the possibility of creating a su bstant ial reduction in the number of coronary events.
Diet is the first and continuing line of treatment for lowering and maintaining blood cholesterol levels. Where dietary intervention is not sufficient to reduce especially elevated LDL cholesterol levels significantly after a period of 3 to 6 months, drugs may be important. The benefits of drug treatment in these individuals far outweigh the infrequent risks.
Years of research have produced important information linking elevated blood cholesterol levels to CHD and linking the redu ction of elevated cholesterol level s to a reduction in CHD risk. The 1988 Surgeon General's Report concluded that reducing high levels of saturated fat and cholesterol in the American diet will reduce elevated blood cholesterol levels and thus coronary heart disease rates. The National Research Council , after a thorough review of the science. concurred in its 1989 report Diet and Health.
A broad consensus among the international scientific community also exists. This consensus among experts about the validity of the scie nce underscores widespread agreement among organizations interested in public health that a national educational program directed at the prevention and control of high blood cholesterol is important and necessary.
In 1985, more than 35 organizations representing the major profes-sional g rou ps for Un ite d Sta tes health p rofessi on s (includi ng the Ame rican Association of Occupational H ealth Nurses, Inc. ), joined with the N ational H eart, Lung, and Blood In stitute in laun ching the National C holes tero l Education Program. The 19 nation E uropea n Atheroscl e rosi s Soci ety and expe rts from othe r count ries have discussed similar efforts in th e ir ow n countries .
Since 1985, th e National Heart, Lung, and Blood Institute and its partne r organizations in th e Na tional Cholestero l E du cation P rogram have dire cted conside rable en e rgies toward informing health profession als, their clients, and the public about this major risk factor and wh at can be done to control it.
Th is issue of th e AAO HN JO UR-NAL presents three articles th at discuss diet ary and d rug the rapy guideline s and what you as an occ upational health nur se can do in your clinical se tt ing. Remember: all adult Ame rica ns, th ose 20 and olde r, sho uld have th ei r blood choles tero l levels chec ke d at le ast once every 5 yea rs. T hose with e levated blood chol esterol levels should lower th e ir levels and reduce their risk of CH D. Join us in this co nt inuing partn e rsh ip for he alth.
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